These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10228081)

  • 1. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients.
    Casado JL; Valdezate S; Calderon C; Navas E; Frutos B; Guerrero A; Martinez-Beltran J
    J Infect Dis; 1999 Jun; 179(6):1553-6. PubMed ID: 10228081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethoprim-sulfamethoxazole exposure alters ex vivo function of B lymphocytes isolated from human immunodeficiency virus-infected patients receiving Zidovudine.
    Venugopalan V; Thornton AC; Steinke DT; Rapp RP; Romanelli F; Feola DJ
    Pharmacotherapy; 2009 Apr; 29(4):373-82. PubMed ID: 19323617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole.
    Feola DJ; Garvy BA; Rapp RP; Thornton AC
    Pharmacotherapy; 2007 Jul; 27(7):937-47. PubMed ID: 17594199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current aspects of Salmonella bacteremia cases in the Ibrahima Diop Mar Infectious Diseases clinic, Fann National Hospital Center (Senegal)].
    Seydi M; Soumare M; Sow AI; Diop BM; Sow PS
    Med Mal Infect; 2005 Jan; 35(1):23-7. PubMed ID: 15695029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
    Opravil M; Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
    Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
    J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Salmonellosis in HIV infection in a hospital setting in Gabon].
    Okome-Kouakou M; Bekale J; Kombila M
    Med Trop (Mars); 1999; 59(1):46-50. PubMed ID: 10472582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ciprofloxacin: a solution for recurrent bacteremia caused by Salmonella non typhi in acquired immunodeficiency syndrome?].
    Pedro-Botet Montoya J; Tomás Vecina S; Soriano Giménez JC; Rubiés-Prat J
    Enferm Infecc Microbiol Clin; 1989 Oct; 7(8):449-50. PubMed ID: 2490867
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo antagonism with zidovudine plus stavudine combination therapy.
    Havlir DV; Tierney C; Friedland GH; Pollard RB; Smeaton L; Sommadossi JP; Fox L; Kessler H; Fife KH; Richman DD
    J Infect Dis; 2000 Jul; 182(1):321-5. PubMed ID: 10882616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative activities of ciprofloxacin, amoxicillin, and cotrimoxazole in an experimental model of enteritis caused by Salmonella non typhi].
    Gómez-Garcés JL; Castilla C
    Enferm Infecc Microbiol Clin; 1992; 10(7):389-92. PubMed ID: 1450256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of zidovudine in preventing relapses of Salmonella bacteremia in AIDS.
    Salmon D; Detruchis P; Leport C; Bouvet E; Karam D; Meyohas MC; Coulaud JP; Vildé JL
    J Infect Dis; 1991 Feb; 163(2):415-6. PubMed ID: 1988528
    [No Abstract]   [Full Text] [Related]  

  • 17. Schistosomiasis does not contribute to death or recurrence of nontyphoid Salmonella bacteremia in human immunodeficiency virus-infected Malawian adults.
    Gordon MA; Zijlstra EE; Naus CW; Visser LG; Molyneux ME; van Lieshout L
    Clin Infect Dis; 2003 Dec; 37(12):e177-9. PubMed ID: 14689364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
    J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteremia in adult patients with acquired immunodeficiency syndrome in the northeast of Thailand.
    Mootsikapun P
    Int J Infect Dis; 2007 May; 11(3):226-31. PubMed ID: 16815065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.